Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25-35 model of Alzheimer's disease

Alzheimer's and Dementia

Volumn 4, Issue 5, 2008, Pages 332-344

  Galoyan, Armen A ^a   Sarkissian, John S ^a,b   Chavushyan, Vergineh A ^a,b   Meliksetyan, Irina B ^b   Avagyan, Zaruhi E ^b   Poghosyan, Mikhail V ^b   Vahradyan, Hasmik G ^c   Mkrtchian, Hovhannes H ^b   Abrahamyan, Davit O ^d  

^a H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

^b Orbeli Institute of Physiology   (Armenia)

^c YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^d Sargsyan Military Institute   (Armenia)

Author keywords

Amyloid peptide A 25 35; Entorhinal cortex; Hippocampus; Histochemical study; Hypothalamic proline rich peptide PRP 1; Learning in water maze; Tetanic and posttetanic potentiation and depression

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; NEUROPEPTIDE; PLACEBO; PROLINE RICH PEPTIDE 1;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENTATE GYRUS; DISEASE MODEL; ENTORHINAL CORTEX; GLIA CELL; HEMISPHERE; HIPPOCAMPUS; HISTOCHEMISTRY; LEARNING; MALE; MAZE TEST; NERVE CELL STIMULATION; NERVE DEGENERATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; POST TETANIC POTENTIATION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; FEMALE; HIPPOCAMPUS; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; LONG-TERM SYNAPTIC DEPRESSION; MALE; MAZE LEARNING; NEURONS; NEUROPROTECTIVE AGENTS; PROLINE-RICH PROTEIN DOMAINS; RATS; RATS, WISTAR;

EID: 51349168631     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.019     Document Type: Article

References (51)

1. Vickers J.C., Dickson T.C., Adlard P.A., Saunders H.L., King C.E., and McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Progr Neurobiol 60 (2000) 139-165
2. Mattson M.P., and Chan S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34 (2003) 385-397
3. Schmitt H.P. Neuro-modulation, aminergic neuro-disinhibition and neuro-degeneration: draft of a comprehensive theory for Alzheimer disease. Med Hypotheses 65 (2005) 1106-1119
4. Smith I.F., Green K.N., and La Ferla F.M. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 38 (2005) 427-437
5. 2+ channels in central neurons. Neurobiol Aging 27 (2006) 439-445
6. Rowan M.J., Ramsden M., Boyle J.P., Klyubin I., Cullen W.K., and Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci 358 (2003) 821-828
7. Nomura I., Kato N., Kita T., and Takechi H. Mechanism of impairment of long-term potentiation by amyloid β is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci Lett 391 (2005) 1-6
8. Shemer I., Holmgren C., Min R., Fulop L., Zilberter M., Sousa K., et al. Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci 23 (2006) 2035-2047
9. Lesne S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., et al. NMDA receptor activation inhibits α-secretase and promotes neuonal amyloid-β production. J Neurosci 25 (2005) 9367-9377
10. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alz Dis Assoc Disord 20 (2006) S8-S11
11. Jakobsen J.S., Wu C.-C., Redwine J.M., Comery T.A., Arias R., Bowlby M., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103 (2006) 5161-5166
12. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., and Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 26 (2006) 7212-7221
13. LeBlanc A.C. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res 2 (2005) 389-402
14. Schmitt H.P. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses 65 (2005) 259-265
15. Roth A.D., Ramirez G., Alarcon R., and Bernhardi R.V. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res 38 (2005) 381-387
16. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., and Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113 (2006) 1685-1695
17. Hoozemans J.J., Veerhuis R., Rozemuller J.M., and Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 24 (2006) 157-165
18. Baloyannis S.J. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 9 (2006) 119-126
19. Mancuso M., Siciliano G., Filosto M., and Murri L. Mitochondrial dysfunction and Alzheimer's disease: new developments. J Alzheimers Dis 9 (2006) 111-117
20. Onyango I.G., and Khan S.M. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Current Alzheimer Disease 3 (2006) 339-349
21. Galoyan A.A. Biochemistry of novel cardioactive hormones and immunomodulators of the functional system neurosecretory hypothalamus-endocrine heart (1997), Nauka publishers, Moscow
22. Markossian K.A., Gurvits B.Y., and Galoyan A.A. Isolation and identification of novel peptides from secretory granules of neurohypophysis (in Russian). Neurochemical Journal (Moscow) 16 (1999) 22-25
23. Galoyan A.A., Terio N., Berg M., and Marks N. Effects of proline-rich peptide derived from Neurophysin-II on caspases of murine neuroblastoma: evidences for caspase-2 and -6 activation. Neurochemical Journal (Moscow) 17 (2000) 185-188
24. Galoyan A.A., Sarkissian J.S., Kipriyan T.K., Sarkissian E.J., Grigorian Y.K., Sulkhanyan R.M., et al. Protection against neuronal injury by hypothalamic peptides and by dexamethasone. Neurochem Res 25 (2000) 1567-1578
25. Galoyan A.A., Krieglstein J., Klumpp S., Danielian K., Galoian K., Kremers W., et al. Effect of hypothalamic proline-rich peptide (PRP-1) on neuronal and bone marrow cell apoptosis. Neurochem Res 32 (2007) 1898-1905
26. Galoyan A.A. Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res 25 (2001) 1343-1355
27. Galoyan A.A., Sarkissian J.S., Kipriyan T.K., Sarkissian E.J., Chavushyan V.A., Sulkhanyan R.M., et al. Protective effect of the new hypothalamic peptides against cobra venom and trauma induced neuronal injury. Neurochem Res 26 (2001) 1023-1038
28. Abrahamyan S.S., Meliksetyan I.B., Sulkhanyan R.M., Sarkissian J.S., and Galoyan A.A. Immunohistochemical study of immunophilin 1-15 fragment in intact frog brain, and in the brain and spinal cord of intact and spinal cord hemisectioned rats. Neurochem Res 269 (2001) 1225-1230
29. Abrahamyan S.S., Sarkissian J.S., Meliksetyan I.B., and Galoyan A.A. Survival of trauma-injured neurons in rat brain by treatment with proline-rich peptide (PRP-1): an immunohistochemical study. Neurochem Res 29 (2003) 695-708
30. Galoyan A.A., Sarkissian J.S., Sulkhanyan R.M., Chavushyan A.J., Gevorgyan Z.A., Avetisyan Z.E., et al. PRP-1 protective effect against central and peripheral neurodegeneration following n. ischiadicus transection. Neurochem Res 30 (2005) 487-505
31. Galoyan A.A., Sarkissian J.S., Chavushyan E.A., Sulkhanyan R.M., Avakyan Z.E., Avetisyan Z.A., et al. Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection. Neurochem Res 30 (2005) 507-525
32. Sarkissian J.S., Yaghjyan G.V., Abrahamyan D.O., Chavushyan V.A., Meliksetyan I.B., Poghosyan M.V., et al. Acceleration of peripheral nerve regeneration by hypothalamic proline-rich peptide PRP-1 (Galarmin) (in Russian). Annals of Plastic Reconstructive and Aesthetic Surgery 4 (2005) 19-30
33. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed (1986), Academic Press, New York
34. Maurice T., and Privat A. Sigma1 receptor agonists and neurosteroids attenuate β25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neurosci 83 (1998) 413-428
35. Meliksetyan I.B. The revealing of myelin sheets of the central nervous system nerve fibers (in Russian). Morfologia (Saint-Petersburg) 123 (2003) 91-92
36. 2+-dependent activity of acid phosphatase in cell structures of rat brain (in Russian). Morfologia (Saint-Petersburg) 129 (2006) 66
37. Markowska A.L., Price D., and Kollatsos V.E. Selective effects of nerve growth factor on spatial recent memory as assessed by delayed no matching-to-position task in the water maze. J Neurosci 16 (1996) 3541-3548
38. Pereira C., Agostinho P., Moreira P.I., Cardoso S.M., and Oliveira C.R. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 4 (2005) 383-403
39. Lleo A., Greenberg S.M., and Growdon J.H. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57 (2006) 1-7
40. Zhao X., Marszalec W., Toth P.T., Huang J., Yeh J.Z., and Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51 (2006) 1181-1191
41. Craft J.M., Watterson D.M., and Van Eldik L.J. Human amyloid β-induced neuroinflammation is an early event in neurodegeneration. Glia 53 (2006) 484-490
42. Bazan N., Marcheselli V., and Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci 1053 (2005) 137-147
43. Greenberg D.A., and Jin K. Neurodegeneration and neurogenesis: focus on Alzheimer's disease. Curr Alzheimer Res 3 (2006) 25-28
44. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson-Wood K., et al. Games β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 25 (2005) 9096-9101
45. Brendza R.P., Bacskai B.J., Cirrito J.R., Simmons K.A., Skoch J.M., Klunk W.E., et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115 (2005) 428-433
46. Brendza R.P., and Holtzman D.M. Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 20 (2006) 118-123
47. Okura Y., Mlyakoshi A., Kohyama K., Park L.-K., Staufenbiel M., and Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A 25 (2006) 9619-9624
48. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006 (2006) 31372
49. Simard A.R., and Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry 11 (2006) 327-335
50. Hambartsumyan D.K., Vardanyan F.G., Gevondyan K.A., Kamalyan R.G., and Galoyan A.A. The influence of proline-rich peptide on the activity of the system of neuromediatory amino acids of glutamine-glutamate-GABA (in Russian). Neurochemical Journal (Moscow) 20 (2003) 145-152
51. 14C-glucose and uptake of 14C-glutamine acid in crush syndrome. PhD Thesis, Yerevan, Armenia, 2000.